Abstract:Purpose: The purpose of this preliminary study was to assess the feasibility and efficacy of intraoperative, ultrasound-guided 125I seed interstitial brachytherapy for unresectable pancreatic carcinoma.Materials and Methods: 27 patients were diagnosed with unresectable pancreatic carcinoma that was not considered curable during laparotomy. Twelve patients with were diagnosed with stage II/III carcinoma, and fifteen patients with stage IV carcinoma. These patients were treated with 125I seed implantation guided by intraoperative ultrasound. The matched peripheral doses (MPD) of 125I resulting from seed implantation ranged from 110 Gy to 160 Gy. A subset of seven patients received additional external beam radiotherapy (EBRT) with a total dose of EBRT administered between 3500∼4500 cGy at 200 cGy per fraction. Six patients received 2–6 cycles of chemotherapy.Results: Of the 20 patients treated with 125I seed implantation only, 85% (17/20) experienced pain relief, while 15% (3/20) did not respond. The median time of pain relief was 5 days and ranged from 1 to 30 days. The overall median survival time in this study was 8 months (95% CI: 6.6–9.4). One- and two-year survival rates of 19.5% and 7.8% were observed, and local control of disease was achieved in 74% patients (20/27). For stage II and III patients, the one- and two-year survival rates were 33.9% and 16.9%, respectively, and the median survival was 10 months (95% CI: 7.8–12.2). In contrast, for stage IV patients the one-and two-year survival rates were 7.1% and 0%, with a median survival of 6 months (95% CI: 2.3–9.7). For patients receiving seed implant plus EBRT versus seed only, the median survival times were 9 and 7 months, respectively (p = 0.1008). For patients receiving seed implants and chemotherapy versus seeds only, the median survival rates were the same, 8 months (p = 0.2954). There were no deaths related to 125I seed implantation.Ultrasound scan show the seed distribution in tumor after seed implant. Purpose: The purpose of this preliminary study was to assess the feasibility and efficacy of intraoperative, ultrasound-guided 125I seed interstitial brachytherapy for unresectable pancreatic carcinoma. Materials and Methods: 27 patients were diagnosed with unresectable pancreatic carcinoma that was not considered curable during laparotomy. Twelve patients with were diagnosed with stage II/III carcinoma, and fifteen patients with stage IV carcinoma. These patients were treated with 125I seed implantation guided by intraoperative ultrasound. The matched peripheral doses (MPD) of 125I resulting from seed implantation ranged from 110 Gy to 160 Gy. A subset of seven patients received additional external beam radiotherapy (EBRT) with a total dose of EBRT administered between 3500∼4500 cGy at 200 cGy per fraction. Six patients received 2–6 cycles of chemotherapy. Results: Of the 20 patients treated with 125I seed implantation only, 85% (17/20) experienced pain relief, while 15% (3/20) did not respond. The median time of pain relief was 5 days and ranged from 1 to 30 days. The overall median survival time in this study was 8 months (95% CI: 6.6–9.4). One- and two-year survival rates of 19.5% and 7.8% were observed, and local control of disease was achieved in 74% patients (20/27). For stage II and III patients, the one- and two-year survival rates were 33.9% and 16.9%, respectively, and the median survival was 10 months (95% CI: 7.8–12.2). In contrast, for stage IV patients the one-and two-year survival rates were 7.1% and 0%, with a median survival of 6 months (95% CI: 2.3–9.7). For patients receiving seed implant plus EBRT versus seed only, the median survival times were 9 and 7 months, respectively (p = 0.1008). For patients receiving seed implants and chemotherapy versus seeds only, the median survival rates were the same, 8 months (p = 0.2954). There were no deaths related to 125I seed implantation. Ultrasound scan show the seed distribution in tumor after seed implant.

Evolution of Interstitial Brachytherapy for Pancreatic Cancer

Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.

Progress of Clinical Brachytherapy Application

Advances Of Stereotactic Body Radiotherapy In Pancreatic Cancer

The Current Research of Intra-Arterial Chemotherapy on Pancreatic Cancer

Intraoperative Ultrasound-Guided 125I Implantation in the Treatment of Unresectable Pancreatic Carcinoma

Ultrasound-guided interstitial ~(125)I seed implantation in the treatment of locally advanced pancreatic carcinoma

Immunotherapy in Pancreatic Cancer: New Hope or Mission Impossible?

Guidelines for permanent iodine-125 seed interstitial brachytherapy for pancreatic cancer (2023 edition): The Chinese expert consensus workshop report

Radiation Therapy for Pancreatic Carcinoma

Advancements and Challenges in Interstitial Brachytherapy Using Iodine-125 Seeds

Precision Interventional Brachytherapy: A Promising Strategy Toward Treatment of Malignant Tumors

Brachytherapy for cervical cancer: from intracavitary to interstitial technique

Efficacy and Safety of CT-guided 125I Seed Implantation for Treatment of Advanced Pancreatic Cancer: a Meta-analysis

Synergistic Effects of 125I Seed Implantation Brachytherapy and Gemcitabine in Pancreatic Tumors

Intratumoral Radiofrequency Hyperthermia-Enhanced Direct Chemotherapy of Pancreatic Cancer

An Overview of the Development of Image-Guided Interventional Brachytherapy in Mainland China

[Intraoperative 125I Brachytherapy Combined with Chemotherapy for Pancreatic Cancer].

Clinical Studies of Pancreatic Cancer Treated by Endovascular Implantation of Iodine-125 Seeds Strand

Expert Consensus on 3D-Printing Template Assisted CT-guided Radioactive 125I Seed Implantation Brachytherapy

Clinical Research of 3d Printing Template-assisted 125 I Radioactive Seed Interstitial Brachytherapy for Malignant Tumors